Why Eiger BioPharmaceuticals Stock Sank Today

Why Eiger BioPharmaceuticals Stock Sank Today

Shares of Eiger BioPharmaceuticals (NASDAQ: EIGR) were sinking 18.9% lower as of 3:22 p.m. EDT on Monday. The big decline came after the company announced disappointing results from an investigator-sponsored clinical study evaluating Peginterferon Lambda-1a (Lambda) in treating outpatients with mild and uncomplicated COVID-19. Stanford University School of Medicine conducted the study of Lambda in treating COVID-19 patients.